5-Methylcytosine (m5 C) is an
RNA modification prevalent on tRNAs, where it can protect tRNAs from endonucleolytic cleavage to maintain
protein synthesis. The NSUN family (NSUN1-7 in humans) of
RNA methyltransferases are capable of installing the methyl group onto the C5 position of cytosines in
RNA. NSUNs are implicated in a wide range of (patho)physiological processes, but selective and cell-active inhibitors of these
enzymes are lacking. Here, we use
cysteine-directed activity-based
protein profiling (ABPP) to discover
azetidine acrylamides that act as stereoselective covalent inhibitors of human NSUN2. Despite targeting a conserved catalytic
cysteine in the NSUN family, the NSUN2 inhibitors show negligible cross-reactivity with other human NSUNs and exhibit good
proteome-wide selectivity. We verify that the
azetidine acrylamides inhibit the catalytic activity of recombinant NSUN2, but not NSUN6, and demonstrate that these compounds stereoselectively disrupt NSUN2-tRNA interactions in
cancer cells, leading to a global reduction in
tRNA m5 C content. Our findings thus highlight the potential to create isotype-selective and cell-active inhibitors of NSUN2 with covalent chemistry targeting a conserved catalytic
cysteine.